多肽CRDMO平台
目录肽
大奖888生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
LL37-002B
LL-37
H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH\nTrifluoroacetate salt
H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH\nTrifluoroacetate salt
Size：5
P1(RMB)：4230
MW：4493.33
One letter sequence：LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Molecular Formula：C205H340N60O53
Description：LL-37 is an antimicrobial peptide with angiogenic activity. It corresponds to the C-terminal sequence (134-170) of the human cathelicidin antimicrobial protein hCAP18/LL-37 and is extracellularly released from hCAP18/LL-37 by proteolytic processing. hCAP18/LL-37 is an effector of the innate immune system and is expressed in leukocytes and epithelial cells where it is upregulated in association with inflammation and injury. An overexpression of hCAP18/LL-37 in a series of breast carcinomas could be demonstated. LL-37 has been suggested to stimulate epithelial cell proliferation partially through formyl peptide receptor-like 1 (FPRL1) since blocking the receptor with pertussis toxin decreased the proliferative effect of LL-37 by approximately 50 %.
Literature Reference：Z.Oren et al., Biochem. J., 341, 501 (1999)\nR.Koczulla et al., J. Clin. Invest., 111, 1665 (2003)\nR.Shaykhiev et al., Am. J. Physiol. Lung Cell. Mol. Physiol., 289, L842 (2005)\nJ.D.Heilborn et al., Int. J. Cancer, 114, 713 (2005)\nG.H. Gudmundsson et al.,Eur. J. Biochem., 238, 325 (1996).\nR. Bals et al., Cell. Mol. Life Sci., 60, 711 (2003) \nM. Zanetti, J. Leukoc. Biol., 75, 39 (2004)\nP.T. Liu et al., Science, 311, 770 (2006). \nR. Lande et al., Nature, 449, 564 (2007). \nP.Y. Ong et al., New Engl. J. Med., 347, 1151 (2002)\nD.W. Hoskin et al., Biochim. Biophys. Acta, 1778, 357 (2008)\nY.P. Lai et al., Trends Immunol., 30, 131 (2009). \nM.F. Burton et al., Nat. Prod. Rep., 26, 1572 (2009).
Cas：154947-66-7
P1(RMB)：4230
MW：4493.33
One letter sequence：LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Molecular Formula：C205H340N60O53
Description：LL-37 is an antimicrobial peptide with angiogenic activity. It corresponds to the C-terminal sequence (134-170) of the human cathelicidin antimicrobial protein hCAP18/LL-37 and is extracellularly released from hCAP18/LL-37 by proteolytic processing. hCAP18/LL-37 is an effector of the innate immune system and is expressed in leukocytes and epithelial cells where it is upregulated in association with inflammation and injury. An overexpression of hCAP18/LL-37 in a series of breast carcinomas could be demonstated. LL-37 has been suggested to stimulate epithelial cell proliferation partially through formyl peptide receptor-like 1 (FPRL1) since blocking the receptor with pertussis toxin decreased the proliferative effect of LL-37 by approximately 50 %.
Literature Reference：Z.Oren et al., Biochem. J., 341, 501 (1999)\nR.Koczulla et al., J. Clin. Invest., 111, 1665 (2003)\nR.Shaykhiev et al., Am. J. Physiol. Lung Cell. Mol. Physiol., 289, L842 (2005)\nJ.D.Heilborn et al., Int. J. Cancer, 114, 713 (2005)\nG.H. Gudmundsson et al.,Eur. J. Biochem., 238, 325 (1996).\nR. Bals et al., Cell. Mol. Life Sci., 60, 711 (2003) \nM. Zanetti, J. Leukoc. Biol., 75, 39 (2004)\nP.T. Liu et al., Science, 311, 770 (2006). \nR. Lande et al., Nature, 449, 564 (2007). \nP.Y. Ong et al., New Engl. J. Med., 347, 1151 (2002)\nD.W. Hoskin et al., Biochim. Biophys. Acta, 1778, 357 (2008)\nY.P. Lai et al., Trends Immunol., 30, 131 (2009). \nM.F. Burton et al., Nat. Prod. Rep., 26, 1572 (2009).
Cas：154947-66-7
